| Literature DB >> 30198910 |
Haider H Dar1, Yulia Y Tyurina1, Karolina Mikulska-Ruminska2,3, Indira Shrivastava1,2, Hsiu-Chi Ting1, Vladimir A Tyurin1, James Krieger2, Claudette M St Croix4, Simon Watkins4, Erkan Bayir1, Gaowei Mao1,5, Catherine R Armbruster6, Alexandr Kapralov1, Hong Wang7, Matthew R Parsek8, Tamil S Anthonymuthu1,5, Abiola F Ogunsola6, Becca A Flitter6, Cody J Freedman9, Jordan R Gaston6, Theodore R Holman9, Joseph M Pilewski10, Joel S Greenberger11, Rama K Mallampalli10,12, Yohei Doi10, Janet S Lee10, Ivet Bahar2, Jennifer M Bomberger6, Hülya Bayır1,5, Valerian E Kagan1,11,13,14,15.
Abstract
Ferroptosis is a death program executed via selective oxidation of arachidonic acid-phosphatidylethanolamines (AA-PE) by 15-lipoxygenases. In mammalian cells and tissues, ferroptosis has been pathogenically associated with brain, kidney, and liver injury/diseases. We discovered that a prokaryotic bacterium, Pseudomonas aeruginosa, that does not contain AA-PE can express lipoxygenase (pLoxA), oxidize host AA-PE to 15-hydroperoxy-AA-PE (15-HOO-AA-PE), and trigger ferroptosis in human bronchial epithelial cells. Induction of ferroptosis by clinical P. aeruginosa isolates from patients with persistent lower respiratory tract infections was dependent on the level and enzymatic activity of pLoxA. Redox phospholipidomics revealed elevated levels of oxidized AA-PE in airway tissues from patients with cystic fibrosis (CF) but not with emphysema or CF without P. aeruginosa. We believe that the evolutionarily conserved mechanism of pLoxA-driven ferroptosis may represent a potential therapeutic target against P. aeruginosa-associated diseases such as CF and persistent lower respiratory tract infections.Entities:
Keywords: Bacterial infections; Cell Biology; Infectious disease
Mesh:
Substances:
Year: 2018 PMID: 30198910 PMCID: PMC6159971 DOI: 10.1172/JCI99490
Source DB: PubMed Journal: J Clin Invest ISSN: 0021-9738 Impact factor: 14.808